AbbVie spies potential in Regenxbio eye disease gene therapyAbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get Share XAbbVie spies potential in Regenxbio eye disease gene therapyhttps://pharmaphorum.com/news/abbvie-spies-potential-in-regenxbio-eye-disease-gene-therapy/
